ClinicalTrials.gg
RecruitingNCT06558188CATUpdated Oct 8, 2026

Combined Anabolic Therapy

A Phase 4 interventional study of Romosozumab and Teriparatide in Osteoporosis, Postmenopausal and Osteoporosis, sponsored by Massachusetts General Hospital. Recruiting at 1 site in United States. Open to female participants aged 45 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-08.

Sponsored by Massachusetts General Hospital · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Feb 2025; still recruiting 1 year 9 months later.
Updated Oct 8, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
45 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 23 studies testing teriparatide in Osteoporosis, Postmenopausal — 1 open to participants now, 1 under way, none of them phase 3. Teriparatide · Osteoporosis, Postmenopausal.

Planned enrollment
16th of 22
50 · median 75
Started
2025
with 1 other
Phase 4
13 of 23
1 open now
Registered
22nd of 23
by date
Lead sponsor
4 of 23
Massachusetts General Hospital

Among the 23 studies testing teriparatide in Osteoporosis, Postmenopausal, this one is the 16th largest by planned enrollment of the 22 interventional ones that give a count, is one of 2 that started in 2025, is one of 13 in phase 4, and was the 22nd registered.

Osteoporosis, Postmenopausal

334 studies on the registry are indexed under Osteoporosis, Postmenopausal; 28 are open to participants now.

Browse Osteoporosis, Postmenopausal studies →

Open to participants now

1 of the 23 studies testing teriparatide in Osteoporosis, Postmenopausal is open now, in 1 country.

By country, each count listing its studies:

About teriparatide

Teriparatide: first FDA approval 2002 (FORTEO), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 20 Osteoporosis, Postmenopausal studies recruiting now, 8 (40%) set no upper age limit and 8 (40%) stop at 75 or younger; 1 takes children under 18; 7 take healthy volunteers.

This study: 45 Years and older · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies testing teriparatide in Osteoporosis, Postmenopausal, or all of them as a file.
02

Study summary

In this research study the study investigators want to learn more about the effect of two different FDA-approved medication regimens in the treatment of postmenopausal osteoporosis.

03

Conditions studied

  • Osteoporosis, Postmenopausal
  • Osteoporosis
04

Who can participate

Ages eligible
45 Years and older
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • women aged 45+
  • osteoporotic with high risk of fracture

Exclusion criteria

Exclusion Criteria:

  • no significant previous use of bone health modifying treatments
  • known congenital or acquired bone disease other than osteoporosis
  • significant renal disease, liver disease, cardiopulmonary disease, or psychiatric disease
  • abnormal calcium or parathyroid hormone level
  • serum vitamin D \<20 ng/dL
  • anemia (hematocrit \<32%)
  • history of (except non-melanoma skin carcinoma)
  • excessive alcohol use or substance abuse
  • known to romosozumab or teriparatide
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
50 participants (estimated)

Study arms

  • Active comparator
    Romosozumab

    romosozumab

    Drug: Romosozumab

  • Active comparator
    Romosozumab and Teriparatide

    romosozumab and teriparatide

    Drug: Romosozumab · Drug: Teriparatide

Interventions

  • romosozumab 210 milligrams monthly

    Also known as: Evenity

  • teriparatide 20 micrograms daily

    Also known as: Forteo

06

What researchers measure

Primary outcomes

  1. Lumbar spine areal bone mineral density

    Change in lumbar spine bone density between month 0 and month 12

    Time frame: Month 0 to 12

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2025 (actual). Primary completion is estimated for Nov 2027, 32 months after the start.

Of 27 phase 4 interventional studies under Osteoporosis, Postmenopausal, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 66. This study's planned 32 months is close to that.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 8, 2026: primary completion Dec 2027 → Nov 2027 and completion Apr 2028 → Nov 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 14, 2024
First posted
Aug 16, 2024
StartActual
Feb 3, 2025
Primary completionEst.
Nov 2, 2027was Dec 2027
CompletionEst.
Nov 19, 2027was Apr 2028
Last update
Oct 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Dec 30, 2027→Nov 2, 2027
Oct 8, 2026
Study completion
Apr 1, 2028→Nov 19, 2027
Oct 8, 2026
Show all 1 update
  1. Oct 8, 2026
    Primary completion Dec 30, 2027→Nov 2, 2027
    Study completion Apr 1, 2028→Nov 19, 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06558188
Responsible party
Benjamin Leder, MD (Professor of Medicine, Massachusetts General Hospital) — Principal investigator
First posted
Aug 16, 2024
Start date
Feb 3, 2025
Primary completion
Nov 2, 2027 (estimated)
Completion
Nov 19, 2027 (estimated)
Last update
Oct 8, 2026

Study contacts

Aparna Patnaik, BA
Contact
apatnaik1@mgh.harvard.edu
617-726-6129
Benjamin Leder, MD
principal investigator · MGH

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Teriparatide

Start the discussion